Media coverage about Abbott Laboratories (NYSE:ABT) has been trending somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abbott Laboratories earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media headlines about the healthcare product maker an impact score of 46.831599500065 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Abbott Laboratories (ABT) Forecasted to Earn Q2 2018 Earnings of $0.72 Per Share (americanbankingnews.com)
- Notable News Recap: Abbott Laboratories, (NYSE: ABT), Walgreens Boots Alliance, Inc., (NASDAQ: WBA) – StocksNewsPro (press release) (stocksnewspro.com)
- Leerink Swann Comments on Abbott Laboratories’ Q4 2018 Earnings (ABT) (americanbankingnews.com)
- Abbott Hosts Conference Call for First-Quarter Earnings (finance.yahoo.com)
- Abbott Laboratories (ABT) Notable Moving Stock – The Stocks News (press release) (thestocksnews.com)
Shares of Abbott Laboratories stock traded down $1.43 during trading hours on Friday, hitting $59.50. The stock had a trading volume of 5,890,862 shares, compared to its average volume of 6,675,876. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.26 and a quick ratio of 1.86. Abbott Laboratories has a one year low of $42.31 and a one year high of $64.60. The firm has a market capitalization of $103,906.88, a price-to-earnings ratio of 228.85, a price-to-earnings-growth ratio of 1.76 and a beta of 1.52.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.88%. The ex-dividend date is Thursday, April 12th. Abbott Laboratories’s payout ratio is 430.79%.
Several analysts recently commented on the company. Barclays upped their target price on Abbott Laboratories from $66.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, January 25th. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Abbott Laboratories in a report on Thursday, January 25th. Royal Bank of Canada reiterated a “buy” rating and issued a $67.00 target price on shares of Abbott Laboratories in a report on Thursday, January 25th. Leerink Swann reiterated a “market perform” rating and issued a $68.00 target price (up from $60.00) on shares of Abbott Laboratories in a report on Thursday, January 25th. Finally, Citigroup increased their price target on Abbott Laboratories from $59.00 to $64.00 and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $65.47.
In other news, SVP Jared Watkin sold 996 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $58.87, for a total transaction of $58,634.52. Following the transaction, the senior vice president now directly owns 69,511 shares of the company’s stock, valued at $4,092,112.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen R. Fussell sold 56,401 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $59.61, for a total value of $3,362,063.61. Following the completion of the sale, the insider now directly owns 184,884 shares of the company’s stock, valued at $11,020,935.24. The disclosure for this sale can be found here. Insiders have sold 124,261 shares of company stock worth $7,559,987 over the last ninety days. 0.76% of the stock is owned by insiders.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.